Galux Secures $29 Million Series B to Advance AI-Driven Protein Design Platform
Key Insights
Galux (search), a South Korea-based biotech company, closed a $29 million Series B financing round, bringing its total capital raised to $47 million to advance AI-driven protein therapeutics design.
The company's GaluxDesign platform has successfully generated high-affinity antibodies across multiple therapeutic targets, with AI-designed structures showing high consistency with experimental cryo-EM structures.
Galux (search) is expanding its strategic partnerships globally, including co-development relationships with Celltrion and LG Chem (search), and a recent collaboration with Boehringer Ingelberg.
South Korea-based biotech company Galux (search) has successfully closed a $29 million Series B financing round, bringing the company's total capital raised to $47 million. The funding will advance the company's AI-driven protein therapeutics design platform and support expansion into more challenging therapeutic targets.
AI Platform Demonstrates Precision in Antibody Design
At the center of Galux (search)'s technology is GaluxDesign, an AI-driven platform focused on de novo antibody design. The platform has generated high-affinity antibodies across multiple therapeutic targets and demonstrated remarkable precision when an AI-designed antibody structure showed high consistency with a cryo-EM experimental structure, which the company characterized as evidence of both precision and generalizability.
The company integrates its AI capabilities with experimental feedback from an internal wet lab to improve platform performance. Building on this foundation, Galux (search) is extending its efforts to more challenging target classes, including GPCRs (search) and ion channels (search).
Strategic Funding and Investment Support
The Series B round included participation from existing backers InterVest (search), DAYLI Partners (search), and PATHWAY Investment (search), along with new investors including Yuanta Investment (search), Korea Development Bank (search) (KDB), SL Investment (search), NCORE Ventures (search), SneakPeek Investments (search), Korea Investment & Securities (search), and Mirae Asset Securities (search).
"Since our initial seed investment, Galux (search) has consistently demonstrated strong technical depth and disciplined execution," said Sang-gyun Kim, Ph.D, Executive Managing Director at InterVest (search). "The company's capability to build a globally competitive AI platform for de novo protein design strengthens our conviction in its technology and its long-term potential to transform drug discovery."
Galux (search) previously raised an $18 million Series A in 2022, which helped expand its AI platform and R&D capabilities ahead of the current Series B round.
Next-Generation Approach to Protein Design
The new capital will be used to advance a next-generation approach to protein design that moves beyond "binder design" by incorporating functional activity and developability, with the aim of producing molecules that are more robust and therapeutically viable. The company also plans to expand R&D infrastructure and accelerate preclinical validation for proprietary programs.
Global Partnership Expansion
Galux (search) is expanding its strategic partnerships as part of its push to grow globally. The company has established co-development relationships with major pharmaceutical companies including Celltrion and LG Chem (search), and recently announced a collaboration with Boehringer Ingelheim, marking an important step in its international expansion strategy.